Journal of Diabetes and Its Complications
Volume 17, Issue 4 , Pages 218-228 , July 2003

The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones

  • Andrew S. Greenberg

      Affiliations

    • Corresponding Author InformationJean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 136 Harrison Avenue, Boston, MA 02111, USA. Tel.: +1-617-556-3144

Received 2 October 2002 ,Revised 20 December 2002 ,Accepted 30 December 2002.

References 

  1. Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Current Cardiology Reports. 1999;1:99–104
  2. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?. Journal of Clinical Endocrinology and Metabolism. 2001;86:3250–3256
  3. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002;25(Suppl. 1):S74–S77
  4. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(Suppl. 1):S33–S49
  5. Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. Journal of the American College of Cardiology. 1996;27:560–566
  6. Ardissino D, Merlini PA, Arlens R, Coppola R, Bramucci E, Lucreziotti S, et al. Tissue factor in human coronary atherosclerotic plaques. Clinica Chimica Acta. 2000;291:235–240
  7. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23:1605–1611
  8. Aubert J, Safonova I, Negrel R, Ailhaud G. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochemical and Biophysical Research Communications. 1998;250:77–82
  9. Bakris, G., Viberti, G., Weston, W., Heise, M., Porter, L. E., & Freed, M. I. (2003). Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. Journal of Human Hypertension, 17, 7–12.
  10. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001;24:654–658
  11. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14:1132–1143
  12. Blackburn R, Giral P, Bruckert E, Andre JM, Gonbert S, Bernard M, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arteriosclerosis, Thrombosis and Vascular Biology. 2001;21:1962–1968
  13. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25:1135–1141
  14. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Bonadonna RC, Muggeo M. Prevalence rates, additional clinical features and risk of atherosclerosis in subjects with isolated insulin resistance and in subjects with the plurimetabolic syndrome. Diabetes. 2000;49(Suppl. 1):A385
  15. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–1649
  16. Bouloumié A, Bauersachs J, Linz W, Scholkens BA, Wiemer G, Fleming I, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30:934–941
  17. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. Journal of Clinical Investigation. 1995;96:354–360
  18. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research. 2000;87:840–844
  19. Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease: a novel therapeutic target. Journal of Clinical Pharmacology. 1997;37:991–1000
  20. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis and Vascular Biology. 2001;21:365–371
  21. Cominacini L, Garbin U, Fratta PA, Campagnola M, Davoli A, Foot E, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998;47:130–133
  22. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–687
  23. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. American Journal of Physiology. 1993;265:R726–R732
  24. Durante W, Sen AK, Sunahara FA. Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. British Journal of Pharmacology. 1988;94:463–468
  25. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1 beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis and Rheumatism. 2001;44:595–607
  26. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47
  27. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131–1137
  28. Freed M, Fuell D, Menci L, Heise M, Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(Suppl. 1):A267
  29. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. American Journal of Cardiology. 2002;90:947–952
  30. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arteriosclerosis and Thrombosis. 1992;12:461–467
  31. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. American Journal of Cardiology. 1995;76:24C–33C
  32. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Journal of Clinical Investigation. 1994;94:2493–2503
  33. Gan X, Wong B, Wright SD, Cai TQ. Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. Journal of Interferon and Cytokine Research. 2001;21:93–98
  34. Garg R, Kumbkami Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000;36:430–435
  35. Gerich JE. Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM). Hormone and Metabolic Research. 1996;28:404–412
  36. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkami Y, Assian E, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. Journal of Clinical Endocrinology and Metabolism. 2001;86:1306–1312
  37. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997;46:433–439
  38. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. Journal of Cardiovascular Pharmacology. 1999;33:798–806
  39. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology. 2001;31:2857–2865
  40. Gray RP, Yudkin JS. Chapter 57. Cardiovascular disease in diabetes mellitus. In:  Pickup JC,  Williams G editor. Textbook of diabetes. Oxford: Blackwell; 1997;p. 1–57
  41. Greenberg A, Haffner S, Weston W, Fuell D, Christal J, Jones NP, et al. Rosiglitazone reduces C-reactive protein, a marker of systemic inflammation in type 2 diabetic patients. Diabetologia. 2001;44(Suppl. 1):A222
  42. Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Teppo AM, et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993;36:642–647
  43. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes, Obesity and Metabolism. 1999;1(Suppl. 1):S1–S7
  44. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovascular Research. 1999;41:323–333
  45. Haffner S, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  46. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3–9
  47. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. International Journal of Clinical Practice Supplement. 2001;121:19–25
  48. Hanefeld M, Goke B. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes. 2000;108:S256–S266
  49. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. Journal of Clinical Investigation. 1986;77:757–761
  50. Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Jorkander I, Riksson SV, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis Study in Stockholm. Circulation. 1997;95:2380–2386
  51. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Journal of Clinical Investigation. 2002;109:1321–1326
  52. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. American Heart Journal. 2001;141:211–217
  53. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, et al. Troglitazone has a scavenging effect on the reactive oxygen species. Biochemical and Biophysical Research Communications. 1997;235:113–116
  54. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19:151–156
  55. Jones NP, Charbonnel B, Lönnqvist F, Owen S. Rosiglitazone reduces plasma insulin and its precursors while decreasing glycaemia in type 2 diabetics. Diabetologia. 1999;42(Suppl. 1):A229
  56. Jones NP, Mather R, Owen S, Porter LE, Patwardhan R. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. Diabetologia. 2000;43(Suppl. 1):A192
  57. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Annals of Medicine. 2000;32(Suppl. 1):78–84
  58. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457–462
  59. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochemical and Biophysical Research Communications. 1999;258:431–435
  60. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology, Endocrinology and Metabolism. 2001;280:E745–E751
  61. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technology and Therapeutics. 2002;4:145–151
  62. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  63. Kobayashi M. Effects of current therapeutic interventions on insulin resistance. Diabetes, Obesity and Metabolism. 1999;1(Suppl. 1):S32–S40
  64. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. New England Journal of Medicine. 2000;342:1792–1801
  65. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2001;86:3452–3456
  66. Kotchen TA, Zhang HY, Reddy S, Hoffmann RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. American Journal of Physiology. 1996;270:R660–R666
  67. Kylin E. Studien ueber das Hypertonie-Hyperlglykämie-Hyperurikämiesyndrom. Zentralblatt fuer Innere Medizin. 1923;44:105–127
  68. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311–1318
  69. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2001;86:280–288
  70. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arteriosclerosis, Thrombosis and Vascular Biology. 1996;16:1070–1073
  71. Lehr HA, Becker M, Marklund SL, Hubner C, Arfors KE, Kohlschutter A, et al. Superoxide-dependent stimulation of leukocyte adhesion by oxidatively modified LDL in vivo. Arteriosclerosis and Thrombosis. 1992;12:824–829
  72. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. Journal of Clinical Investigation. 2000;106:523–531
  73. Lingohr MK, Buettner R, Rhodes CJ. Pancreatic beta-cell growth and survival—a role in obesity-linked type 2 diabetes?. Trends in Molecular Medicine. 2002;8:375–384
  74. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31:40–47
  75. Lyons TJ, Li W, Wells-Knecht MC, Jokl R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 1994;43:1090–1095
  76. Mao D, Lee JK, VanVickle SJ, Thompson RW. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochemical and Biophysical Research Communications. 1999;261:904–910
  77. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arteriosclerosis and Thrombosis. 1994;14:1741–1745
  78. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arteriosclerosis, Thrombosis and Vascular Biology. 1999;19:546–551
  79. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. American Journal of Pathology. 1998;153:17–23
  80. Mason DP, Kenagy RD, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodelling in the injured rat carotid artery. Circulation Research. 1999;85:1179–1185
  81. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinolgy and Metabolism. 2002;87:2784–2791
  82. Mohanty P, Aljada A, Ghanim H, Tripathy D, Syed T, Hofmeyer D, et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. Diabetes. 2001;50(Suppl. 2):A68
  83. Murao K, Ohyama T, Imachi H, Ishida T, Cao WM, Namihira H, et al. TNF-alpha stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Biochemical and Biophysical Research Communications. 2000;276:791–796
  84. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. Journal of Diabetes and Its Complications. 2000;14:250–254
  85. Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabetic Medicine. 2001;18:308–313
  86. NCEP Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association. 2001;285:2486–2497
  87. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. American Journal of Hypertension. 1995;8:316–320
  88. Panza JA. Endothelial dysfunction in essential hypertension. Clinical Cardiology. 1997;20:26–33
  89. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  90. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association. 2001;286:327–334
  91. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arteriosclerosis, Thrombosis and Vascular Biology. 2000;20:645–651
  92. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proceedings of the National Academy of Sciences of the United States of America. 1987;84:2995–2998
  93. Quinones MJ, Pampaloni MH, Juarez BE, Wang Y, Carmona GC, Van Herle K, et al. Insulin resistance in healthy Mexican Americans is associated with coronary artery endothelial dysfunction. Diabetes. 2000;49(Suppl. 1):A146
  94. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. Journal of Immunology. 1995;155:3610–3618
  95. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  96. Rhodes CJ, White MF. Molecular insights into insullin action and secretion. European Journal of Clinical Investigation. 2002;32(Suppl. 3):3–13
  97. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79–82
  98. Sakai M, Miyazaki A, Hakamata H, Sato Y, Matsumura T, Kobori S, et al. Lysophosphatidycholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arteriosclerosis, Thrombosis and Vascular Biology. 1996;16:600–605
  99. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect?. Drug Safety. 2001;24:873–888
  100. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. Journal of Biological Chemistry. 1997;272:21609–21615
  101. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proceedings of the National Academy of Sciences of the United States of America. 1992;89:6998–7002
  102. Shimono D, Kuwamura N, Nakamura Y, Koshiyama H. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes. Diabetes Care. 2001;24:971
  103. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97:2213–2221
  104. St. John Sutton MS, Dole JF, Rappaport EB. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes. Diabetes. 1999;48(Suppl. 1):A102
  105. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Intervention Trial. Diabetes Care. 1993;16:434–444
  106. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. Journal of Clinical Investigation. 1996;97:2601–2610
  107. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 1998;21:796–799
  108. Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012–2020
  109. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241–2247
  110. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. New England Journal of Medicine. 1995;332:635–641
  111. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. Journal of the American College of Cardiology. 2000;36:2185–2191
  112. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. Journal of Internal Medicine. 2000;247:425–431
  113. Turner R, Cull CA, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Annals of Internal Medicine. 1996;124:136–145
  114. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  115. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853
  116. Watanabe T, Pakala R, Katagiri T, Benedict CR. Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. Journal of Hypertension. 2001;19:1065–1073
  117. Watanabe Y, Sunayama S, Shimada K, Sawano M, Hoshi S, Iwama Y, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. Journal of Atherosclerosis and Thrombosis. 2000;7:159–163
  118. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis. 2002;161:233–242
  119. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. Journal of Laboratory and Clinical Medicine. 1985;105:265–270
  120. Winquist RJ, Bunting PB, Baskin EP, Wallace AA. Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats. Journal of Hypertension. 1984;2:541–545
  121. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: The Third National Health and Nutrition Examination Survey, 1988–1994. American Journal of Epidemiology. 2002;155:65–71
  122. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. Journal of Biological Chemistry. 1999;274:9116–9121
  123. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–1677
  124. Zhu E, Egan JW. The effect of lipid reducing drugs on the serum lipid profile in pioglitazone-treated patients. Diabetes. 2000;49(Suppl. 1):A366
  125. Zinman B. PPARγ agonists in type 2 diabetes: how far have we come from “preventing the inevitable”? A review of the metabolic effects of rosiglitazone. Diabetes, Obesity and Metabolism. 2001;3(Suppl. 1):S34–S43

PII: S1056-8727(03)00002-3

doi: 10.1016/S1056-8727(03)00002-3

Journal of Diabetes and Its Complications
Volume 17, Issue 4 , Pages 218-228 , July 2003

Article Tools

* Image Usage & Resolution